# Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

Source: https://onco.cc/trials/nct07234877/  
OnCo record `nct07234877` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ivonescimab, carboplatin, pemetrexed, paclitaxel / nab-paclitaxel and other drugs in lung cancer, run by European Organisation for Research and Treatment of Cancer - EORTC, not yet recruiting.

## Summary

Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets is a phase 2, randomised interventional study registered as NCT07234877 by European Organisation for Research and Treatment of Cancer - EORTC, with a registry enrolment figure of 158 participants, started 2026-11 and due to reach its primary completion in 2032-01. Interventions recorded: Ivonescimab; Carboplatin; Pemetrexed; Paclitaxel; Paclitaxel-albumin; Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiotherapy (FSRT). Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Intracranial progression-free survival based on local assessment using RANO-BM criteria. Lung eligibility wording from the registry: "* Patients with pathology proven metastatic NSCLC without an actionable genomic alteration for which there is first line targeted treatment approved by EMA and recommended by the ESMO guidelines". Sites: Austria, France, Germany, Greece, Italy, Netherlands, Slovenia, Spain. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07234877
- Phase: 2
- Setting: A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC
- Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Enrolled: 158

## Sources

- ClinicalTrials.gov NCT07234877: https://clinicaltrials.gov/study/NCT07234877

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Summit Therapeutics](https://onco.cc/companies/summit-therapeutics/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07234877.json